Improving Assay Sensitivity In Phase 3 Trials: Existing Data - immpact

More documents

Recommendations

Info

16 additional recent “negative” neuropathicpain trials (and there are many others)Bicifadine in painful DPNGabapentin enacarbil in painful DPNLacosamide in painful DPN (2 trials)Lamotrigine in painful DPN (2 trials)Lamotrigine in mixed neuropathic pain conditionsLevetiracetam in postherpetic neuralgiaOxcarbazepine in painful DPN (2 trials)Oxcarbazepine in lumbosacral radiculopathyPregabalin in painful DPNPregabalin in lumbosacral radiculopathyTopiramate in painful DPN (3 trials)
For most of these results, we do not knowwhich are examples of “drug failure” —perhaps some of these drugs are notefficacious in the specific neuropathic painconditions in which they were studiedand which are examples of “study failure” —some are likely to be failed studies of trulyefficacious drugsfor example, pregabalin in painful DPN
Page 1 and 2: Improving assaysensitivity in Phase
Page 6 and 7: “Insanity: doing the samething ov
Page 8 and 9: Some recent findings on placebo eff
Page 10 and 11: What approaches can be used tooptim
Page 12 and 13: Patient factors that may be associa
Page 14 and 15: “Individuals with a greater PVI (
Page 17 and 18: “...Though it is natural to hope
Page 20 and 21: Investigator factors that may be as
Page 22: Can Phase 3 trials continue to excl

Improving Assay Sensitivity In Phase 3 Trials: Existing Data - immpact

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?